DE69902103D1 - Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin - Google Patents

Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin

Info

Publication number
DE69902103D1
DE69902103D1 DE69902103T DE69902103T DE69902103D1 DE 69902103 D1 DE69902103 D1 DE 69902103D1 DE 69902103 T DE69902103 T DE 69902103T DE 69902103 T DE69902103 T DE 69902103T DE 69902103 D1 DE69902103 D1 DE 69902103D1
Authority
DE
Germany
Prior art keywords
lamivudine
hepatitis
treatment
thymosin alpha
antiviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69902103T
Other languages
English (en)
Other versions
DE69902103T2 (de
Inventor
Ying-Kit Leung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Application granted granted Critical
Publication of DE69902103D1 publication Critical patent/DE69902103D1/de
Publication of DE69902103T2 publication Critical patent/DE69902103T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69902103T 1998-09-25 1999-09-22 Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin Expired - Lifetime DE69902103T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10177198P 1998-09-25 1998-09-25
US09/168,869 US6288033B1 (en) 1998-09-25 1998-10-09 Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir
PCT/US1999/021954 WO2000018417A2 (en) 1998-09-25 1999-09-22 Treatment of hepatitis b infection with thymosin alpha 1 and lamivudine

Publications (2)

Publication Number Publication Date
DE69902103D1 true DE69902103D1 (de) 2002-08-14
DE69902103T2 DE69902103T2 (de) 2003-02-27

Family

ID=26798617

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69902103T Expired - Lifetime DE69902103T2 (de) 1998-09-25 1999-09-22 Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin

Country Status (16)

Country Link
US (1) US6288033B1 (de)
EP (1) EP1115420B1 (de)
JP (1) JP2002525333A (de)
CN (1) CN1183964C (de)
AT (1) ATE220332T1 (de)
AU (1) AU757833B2 (de)
BR (1) BR9913951A (de)
CA (1) CA2345462A1 (de)
DE (1) DE69902103T2 (de)
DK (1) DK1115420T3 (de)
ES (1) ES2181502T3 (de)
HK (1) HK1041215B (de)
MX (1) MXPA01003105A (de)
PT (1) PT1115420E (de)
TR (1) TR200100845T2 (de)
WO (1) WO2000018417A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003039582A (ja) * 2001-07-19 2003-02-13 Three M Innovative Properties Co 湿潤防滑性シート及び湿潤防滑構造体
US6855346B2 (en) * 2001-10-05 2005-02-15 Tzu-Sheng Wu Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
PT1448223E (pt) * 2001-10-26 2008-01-23 Rhode Island Hospital Aumento de timosina de imunização genética
US20060259603A1 (en) * 2005-05-16 2006-11-16 Shrader Anthony G User based - workflow and business process management
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
PT2012816E (pt) 2006-05-02 2012-08-17 Sigma Tau Ind Farmaceuti Uso de timosina 1, isolada ou em combinação com ptx3 ou ganciclovir, para o tratamento da infeção por citomegalovírus
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US8716012B2 (en) * 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
CN103458681A (zh) * 2011-02-09 2013-12-18 赛生制药有限公司 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽
JP2016507569A (ja) * 2013-02-07 2016-03-10 トビラ セラピューティクス， インコーポレイテッド ラミブジン結晶塩
US11136378B2 (en) * 2015-11-30 2021-10-05 HBVtech LLC Methods of curing HBV infection and providing complete protection against HBV infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904855D0 (en) 1989-03-03 1989-04-12 Beecham Group Plc Pharmaceutical treatment
US5308833A (en) 1992-02-06 1994-05-03 Sciclone Pharmaceuticals Method for treating hepatitis B carriers with minimal disease
WO1994001125A1 (en) 1992-07-13 1994-01-20 Sherman Kenneth E Composition and method of treating hepatitis b
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir

Also Published As

Publication number Publication date
ATE220332T1 (de) 2002-07-15
US6288033B1 (en) 2001-09-11
CN1183964C (zh) 2005-01-12
DE69902103T2 (de) 2003-02-27
PT1115420E (pt) 2002-11-29
DK1115420T3 (da) 2002-11-04
WO2000018417A3 (en) 2000-07-06
CN1320041A (zh) 2001-10-31
WO2000018417A2 (en) 2000-04-06
EP1115420B1 (de) 2002-07-10
HK1041215B (zh) 2005-08-26
TR200100845T2 (tr) 2001-10-22
AU757833B2 (en) 2003-03-06
AU6057099A (en) 2000-04-17
EP1115420A2 (de) 2001-07-18
ES2181502T3 (es) 2003-02-16
JP2002525333A (ja) 2002-08-13
HK1041215A1 (en) 2002-07-05
CA2345462A1 (en) 2000-04-06
BR9913951A (pt) 2001-06-12
MXPA01003105A (es) 2003-05-15

Similar Documents

Publication Publication Date Title
MY133891A (en) Polyethylene glycol modified interferon therapy
TR200402565T4 (tr) Hepatit delta virüsü enfeksiyonunun tedavi edilmesinde ß-L-2'-deoksi-nükleosidlerin kullanımı
DE60131250T8 (de) Nucleosid-analoga mit monozyklischen basischen carboxamidingruppen
EA199800674A1 (ru) Способ повторного лечения больных гепатитом с
ATE219366T1 (de) Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
ATE473750T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
ITMI931522A1 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
ATE395922T1 (de) Lipid-analoge zur behandlung von viralen infektionen
DE69902103D1 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
DE60237721D1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
ATE320444T1 (de) Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren
ATE339211T1 (de) L-fmau zur behandlung von hepatitis-delta-virus- infizierung
MD990258A (en) Method of treatment of the acute viral hepatitis B
AR036697A1 (es) Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
FR2689398B1 (fr) Compositions destinées au traitement de l'infection et des maladies provoquées par le virus de l'hépatite B (HBV).
DE69428112D1 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
DE69706657D1 (de) Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
ATE348628T1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
DE60002172D1 (de) Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)-2-cyclopenten-1-methanol in hbv
ATE332704T1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
RU98109203A (ru) Способ лечения вирусного гепатита b у детей
MXPA94003453A (es) Metodo y composicion para el tratamiento de pacientes con hepatitis b que tienen descompensacion hepatica.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition